Blueprint Medicines Corp (BPMC)
106.66
-1.83
(-1.69%)
USD |
NASDAQ |
May 10, 16:00
106.66
0.00 (0.00%)
After-Hours: 19:47
Blueprint Medicines Cash from Operations (TTM): -415.40M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -415.40M |
December 31, 2023 | -436.85M |
September 30, 2023 | -479.32M |
June 30, 2023 | -504.73M |
March 31, 2023 | -492.51M |
December 31, 2022 | -502.28M |
September 30, 2022 | -394.99M |
June 30, 2022 | -360.69M |
March 31, 2022 | -305.60M |
December 31, 2021 | -298.65M |
September 30, 2021 | -309.34M |
June 30, 2021 | 408.58M |
March 31, 2021 | 370.58M |
December 31, 2020 | 387.04M |
September 30, 2020 | 366.94M |
June 30, 2020 | -327.09M |
March 31, 2020 | -307.16M |
December 31, 2019 | -278.02M |
September 30, 2019 | -300.70M |
Date | Value |
---|---|
June 30, 2019 | -284.00M |
March 31, 2019 | -205.63M |
December 31, 2018 | -175.01M |
September 30, 2018 | -142.18M |
June 30, 2018 | -113.69M |
March 31, 2018 | -138.35M |
December 31, 2017 | -119.86M |
September 30, 2017 | -103.91M |
June 30, 2017 | -96.03M |
March 31, 2017 | -86.34M |
December 31, 2016 | -24.51M |
September 30, 2016 | -18.76M |
June 30, 2016 | -12.59M |
March 31, 2016 | -5.815M |
December 31, 2015 | -31.68M |
September 30, 2015 | -30.21M |
June 30, 2015 | -26.31M |
March 31, 2015 | -23.90M |
December 31, 2014 | -35.40M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-504.73M
Minimum
Jun 2023
408.58M
Maximum
Jun 2021
-223.21M
Average
-308.25M
Median
Cash from Operations (TTM) Benchmarks
Apellis Pharmaceuticals Inc | -550.10M |
Alnylam Pharmaceuticals Inc | 189.12M |
Ionis Pharmaceuticals Inc | -323.46M |
Madrigal Pharmaceuticals Inc | -389.32M |
Sarepta Therapeutics Inc | -533.67M |